

Food and Drug Administration  
Rockville MD 20857

1032 04 MAR 23 10 49

SP 03P-0552/CP1

MAR 19 2004

Jurox PTY. Limited  
Attention: David Miller  
1312 Ramsay Circle  
Walnut Creek, CA 94597

Dear Mr. Miller:

We refer to your Suitability Petition filed December 1, 2003, in which you requested permission to submit an abbreviated new animal drug application (ANADA) for a generic product with a change in strength and change in dosage form that differ from that of an approved new animal drug. The proposed pioneer product is Pfizer's Rimadyl<sup>®</sup> (carprofen) Caplets which is intended for use in dogs (NADA 141-053).

Your proposed product differs from the pioneer product in strength and dosage form. The proposed generic product is a liquid, which can be administered orally whereas the pioneer is a caplet. The proposed generic product is intended to deliver the same amount of active ingredient per pound of body weight, and is intended for individual animal treatment, as is the pioneer caplet.

Change in strength and change in dosage form are two of the five variances in the pioneer product which can be considered through a Suitability Petition under section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act (FFDCA), as amended. We are required to approve the petition unless we determine that investigations must be conducted to establish the safety and effectiveness of the proposed generic product.

Your Suitability Petition is approved. Approval of the Suitability Petition does not alter the requirements for approval of the ANADA, nor assure approval of the ANADA. Please include a copy of this letter in your generic application.

An *in vivo* bioequivalence study to demonstrate bioequivalence between the pioneer and the generic products will be required. We recommend that you submit protocols for our evaluation before initiating any studies.

We will conduct a definitive labeling review when the ANADA for the proposed generic product is submitted to the Center. The generic labeling should be a verbatim copy of the approved labeling for the pioneer, with certain allowable differences, such as manufacturer's tradename and other appropriate changes.

2003P-0552


PAV 1

SP 03P-0552/CP1

Page 2

You may contact Dr. Lonnie W. Luther, Chief, Generic Animal Drug Team, at 301-827-8549, for any questions on the specific requirements for the ANADA submission.

Sincerely yours,

A handwritten signature in black ink that reads "Steven D. Vaughn, DVM". The signature is written in a cursive style with a large initial 'S'.

Steven D. Vaughn, DVM

Director

Office of New Animal Drug Evaluation  
Center for Veterinary Medicine